Cargando…

A phase I/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours

PURPOSE: We present the results of an open-label, phase I/II study evaluating the safety and efficacy of the novel somatostatin receptor (SSTR) antagonist [(177)Lu]Lu-satoreotide tetraxetan in 40 patients with previously treated, progressive neuroendocrine tumours (NETs), in which dosimetry was used...

Descripción completa

Detalles Bibliográficos
Autores principales: Wild, Damian, Grønbæk, Henning, Navalkissoor, Shaunak, Haug, Alexander, Nicolas, Guillaume P., Pais, Ben, Ansquer, Catherine, Beauregard, Jean-Mathieu, McEwan, Alexander, Lassmann, Michael, Pennestri, Daniele, Volteau, Magali, Lenzo, Nat P., Hicks, Rodney J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684626/
https://www.ncbi.nlm.nih.gov/pubmed/37721581
http://dx.doi.org/10.1007/s00259-023-06383-1
_version_ 1785151445003141120
author Wild, Damian
Grønbæk, Henning
Navalkissoor, Shaunak
Haug, Alexander
Nicolas, Guillaume P.
Pais, Ben
Ansquer, Catherine
Beauregard, Jean-Mathieu
McEwan, Alexander
Lassmann, Michael
Pennestri, Daniele
Volteau, Magali
Lenzo, Nat P.
Hicks, Rodney J.
author_facet Wild, Damian
Grønbæk, Henning
Navalkissoor, Shaunak
Haug, Alexander
Nicolas, Guillaume P.
Pais, Ben
Ansquer, Catherine
Beauregard, Jean-Mathieu
McEwan, Alexander
Lassmann, Michael
Pennestri, Daniele
Volteau, Magali
Lenzo, Nat P.
Hicks, Rodney J.
author_sort Wild, Damian
collection PubMed
description PURPOSE: We present the results of an open-label, phase I/II study evaluating the safety and efficacy of the novel somatostatin receptor (SSTR) antagonist [(177)Lu]Lu-satoreotide tetraxetan in 40 patients with previously treated, progressive neuroendocrine tumours (NETs), in which dosimetry was used to guide maximum administered activity. METHODS: This study was conducted in two parts. Part A consisted of 15 patients who completed three cycles of [(177)Lu]Lu-satoreotide tetraxetan at a fixed administered activity and peptide amount per cycle (4.5 GBq/300 µg). Part B, which included 25 patients who received one to five cycles of [(177)Lu]Lu-satoreotide tetraxetan, evaluated different administered activities (4.5 or 6.0 GBq/cycle) and peptide amounts (300, 700, or 1300 μg/cycle), limited to a cumulative absorbed radiation dose of 23 Gy to the kidneys and 1.5 Gy to the bone marrow. RESULTS: Median cumulative administered activity of [(177)Lu]Lu-satoreotide tetraxetan was 13.0 GBq over three cycles (13.1 GBq in part A and 12.9 GBq in part B). Overall, 17 (42.5%) patients experienced grade ≥ 3 treatment‑related adverse events; the most common were lymphopenia, thrombocytopenia, and neutropenia. No grade 3/4 nephrotoxicity was observed. Two patients developed myeloid neoplasms considered treatment related by the investigator. Disease control rate for part A and part B was 94.7% (95% confidence interval [CI]: 82.3–99.4), and overall response rate was 21.1% (95% CI: 9.6–37.3). CONCLUSION: [(177)Lu]Lu-satoreotide tetraxetan, administered at a median cumulative activity of 13.0 GBq over three cycles, has an acceptable safety profile with a promising clinical response in patients with progressive, SSTR-positive NETs. A 5-year long-term follow-up study is ongoing. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02592707. Registered October 30, 2015. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-023-06383-1.
format Online
Article
Text
id pubmed-10684626
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-106846262023-11-30 A phase I/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours Wild, Damian Grønbæk, Henning Navalkissoor, Shaunak Haug, Alexander Nicolas, Guillaume P. Pais, Ben Ansquer, Catherine Beauregard, Jean-Mathieu McEwan, Alexander Lassmann, Michael Pennestri, Daniele Volteau, Magali Lenzo, Nat P. Hicks, Rodney J. Eur J Nucl Med Mol Imaging Original Article PURPOSE: We present the results of an open-label, phase I/II study evaluating the safety and efficacy of the novel somatostatin receptor (SSTR) antagonist [(177)Lu]Lu-satoreotide tetraxetan in 40 patients with previously treated, progressive neuroendocrine tumours (NETs), in which dosimetry was used to guide maximum administered activity. METHODS: This study was conducted in two parts. Part A consisted of 15 patients who completed three cycles of [(177)Lu]Lu-satoreotide tetraxetan at a fixed administered activity and peptide amount per cycle (4.5 GBq/300 µg). Part B, which included 25 patients who received one to five cycles of [(177)Lu]Lu-satoreotide tetraxetan, evaluated different administered activities (4.5 or 6.0 GBq/cycle) and peptide amounts (300, 700, or 1300 μg/cycle), limited to a cumulative absorbed radiation dose of 23 Gy to the kidneys and 1.5 Gy to the bone marrow. RESULTS: Median cumulative administered activity of [(177)Lu]Lu-satoreotide tetraxetan was 13.0 GBq over three cycles (13.1 GBq in part A and 12.9 GBq in part B). Overall, 17 (42.5%) patients experienced grade ≥ 3 treatment‑related adverse events; the most common were lymphopenia, thrombocytopenia, and neutropenia. No grade 3/4 nephrotoxicity was observed. Two patients developed myeloid neoplasms considered treatment related by the investigator. Disease control rate for part A and part B was 94.7% (95% confidence interval [CI]: 82.3–99.4), and overall response rate was 21.1% (95% CI: 9.6–37.3). CONCLUSION: [(177)Lu]Lu-satoreotide tetraxetan, administered at a median cumulative activity of 13.0 GBq over three cycles, has an acceptable safety profile with a promising clinical response in patients with progressive, SSTR-positive NETs. A 5-year long-term follow-up study is ongoing. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02592707. Registered October 30, 2015. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-023-06383-1. Springer Berlin Heidelberg 2023-09-18 2023 /pmc/articles/PMC10684626/ /pubmed/37721581 http://dx.doi.org/10.1007/s00259-023-06383-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Wild, Damian
Grønbæk, Henning
Navalkissoor, Shaunak
Haug, Alexander
Nicolas, Guillaume P.
Pais, Ben
Ansquer, Catherine
Beauregard, Jean-Mathieu
McEwan, Alexander
Lassmann, Michael
Pennestri, Daniele
Volteau, Magali
Lenzo, Nat P.
Hicks, Rodney J.
A phase I/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
title A phase I/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
title_full A phase I/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
title_fullStr A phase I/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
title_full_unstemmed A phase I/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
title_short A phase I/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
title_sort phase i/ii study of the safety and efficacy of [(177)lu]lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684626/
https://www.ncbi.nlm.nih.gov/pubmed/37721581
http://dx.doi.org/10.1007/s00259-023-06383-1
work_keys_str_mv AT wilddamian aphaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT grønbækhenning aphaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT navalkissoorshaunak aphaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT haugalexander aphaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT nicolasguillaumep aphaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT paisben aphaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT ansquercatherine aphaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT beauregardjeanmathieu aphaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT mcewanalexander aphaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT lassmannmichael aphaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT pennestridaniele aphaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT volteaumagali aphaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT lenzonatp aphaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT hicksrodneyj aphaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT wilddamian phaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT grønbækhenning phaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT navalkissoorshaunak phaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT haugalexander phaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT nicolasguillaumep phaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT paisben phaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT ansquercatherine phaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT beauregardjeanmathieu phaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT mcewanalexander phaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT lassmannmichael phaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT pennestridaniele phaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT volteaumagali phaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT lenzonatp phaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours
AT hicksrodneyj phaseiiistudyofthesafetyandefficacyof177lulusatoreotidetetraxetaninadvancedsomatostatinreceptorpositiveneuroendocrinetumours